Micoisdin

KETOISDIN Cream
Ketoconazole

Composition
Each gram contains:
Ketoconazole (INN)………………. 20 mg
Excipients: propylene glycol, stearyl alcohol, cetyl alcohol, sorbitan monostearate, polysorbate 60,
polysorbate 80, isopropyl myristate, sodium bisulfite and purified water, q.s.
Properties
Ketoisdin (ketoconazole) cream has a potent action against dermatophytes such as Trichophyton
rubrum, T. mentagrophytes and T. tonsurans, Epidermophyton floccosum and Microsporum canis,
against yeasts such as Candida albicans and C. tropicales and against Pityrosporum orbiculare and P.
ovale. In general, Ketoisdin (ketoconazole) cream rapidly reduces itching caused by dermatophyte or
yeast infections. This symptomatic improvement occurs before the first signs of healing are detected,
after just a few days of treatment. Plasma concentrations of ketoconazole are not detectable after
topical application.
Indications
Ketoisdin (ketoconazole) cream is indicated for the topical treatment of dermatophyte infections of
the skin: tinea corporis, tinea cruris, tinea manuum and tinea pedis caused by Trichophyton spp.,
Microsporum spp. and Epidermophyton spp., and for the treatment of cutaneous candidiasis and
pityriasis versicolor.
Ketoisdin (ketoconazole) cream is also indicated for the treatment of seborrhoeic dermatitis caused
by Pityrosporum ovale.

Posology
Ketoisdin (ketoconazole) cream should be applied once daily (preferably at night) to areas affected
by tinea corporis, tinea curis, tinea manuum, tinea pedis, cutaneous candidiasis, seborrhoeic dermatitis
and pityriasis versicolor. Treatment should be continued for sufficient time or until at least a few days
after all symptoms have disappeared.
In severe cases and at the doctor’s discretion, this dose may be increased to up to twice daily (morning
and night).
If no clinical improvement is observed after 4 weeks of treatment, the diagnosis should be
reconsidered. General hygiene measures should be observed to control sources of infection or
reinfection.
The usual duration of treatment is: pityriasis versicolor 2-3 weeks, seborrhoeic dermatitis 2-4 weeks,
yeast infections 2-3 weeks, tinea cruris 2-4 weeks, tinea corporis 3-4 weeks and tinea pedis 4-6 weeks.
If a topical corticosteroid has been used previously in the treatment of seborrhoeic dermatitis, a
recovery period of 2 weeks should be allowed before using Ketoisdin (ketoconazole) cream in order
to reduce the incidence of steroid-induced skin sensitisation which has been reported when no
recovery period has been allowed.
Contraindications
Ketoisdin (ketoconazole) cream should not be administered to patients with a hypersensitivity to any
of its components.
Given that plasma concentrations of ketoconazole are not detectable after topical application, its use
during pregnancy and lactation is not contraindicated. However, potential risks should be assessed
prior to use.

Precautions
Ketoisdin (ketoconazole) cream should not be used for ophthalmic treatments.

Excipients warnings
This medicinal product contains sodium bisulfite as an excipient and may therefore cause allergic
reactions, including anaphylactic reactions and bronchospasm, in susceptible patients, especially in
those with a history of asthma or allergies.

Interactions
No interactions have been reported.
Undesirable effects
In some cases, irritation, dermatitis or a burning sensation may occur during treatment.
Poisoning and its treatment
Due to its pharmaceutical form and method of administration, poisoning is highly unlikely. However,
in the case of accidental ingestion, appropriate symptomatic therapy should be administered. Contact
the Toxicological Information Service on 91 562 04 20

Pack sizes
Cream: Tube containing 30 g.
Subject to medical prescription
KEEP MEDICINES OUT OF THE SIGHT AND REACH OF CHILDREN
Manufactured by:
Laboratorios Dr. Esteve, S.A
Isdin SA
Provençals, 33
08019 Barcelona
Spain

Detailed information on this medicine is available on the Agencia Española de Medicamentos y
Productos Sanitarios (Spanish Agency of Medicines and Medical Devices - AEMPS) web site:
http://www.aemps.es/

Source: http://www.isdin.com/sites/default/files/ftpdf/ketoisdincr_eng.pdf